NLS Pharmaceutics ( (NLSP) ) has issued an announcement.
On March 10, 2025, NLS Pharmaceutics announced significant strategic milestones, including a merger with Kadimastem Ltd., a cell therapy company. This merger aims to create a Nasdaq-traded biotechnology company with advanced therapies for neurodegenerative diseases and diabetes. The merger is expected to close in the second quarter of 2025, pending regulatory approvals. NLS Pharmaceutics is also advancing its diabetes treatment strategies and plans to initiate a Phase IIa clinical trial for ALS treatment post-merger. The company has strengthened its financial position with zero long-term debt and recent private placements, allowing it to pursue strategic partnerships and expand its innovative pipeline.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. Founded in 2015 and headquartered in Switzerland, the company collaborates with world-class partners and scientists to address unmet medical needs in rare and complex CNS disorders.
YTD Price Performance: -22.02%
Average Trading Volume: 2,938,329
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.2M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.